| Literature DB >> 27659931 |
Tatiana De Los Ríos1, Juan Pérez-Martínez2, Jose Portoles3, Monika Lichodziejewska-Niemierko4, Maite Rivera5, Michał Nowicki6, Andrzej Książek6, Ana María Tato7, Christine Bohnhorst8, Mariano Feriani9.
Abstract
Interference of conventional peritoneal dialysis fluids (cPDFs) with peritoneal membrane cell functions may be attributed to the dialysis fluid's low pH, high glucose concentration, and/or the presence of glucose degradation products (GDPs), the last of which leads to higher levels of advanced glycation end-products (AGEs). It has been suggested that the peritoneal membrane might be better preserved by using biocompatible solutions, including cancer antigetn 125 (CA125). This prospective, open-label, multicentre, randomized, controlled, cross-over phase IV study compared the in vivo biocompatibility of a neutral-pH, low-GDP peritoneal dialysis (PD) solution (balance) with a cPDF in automated PD (APD) patients. Our study revealed a significantly increased appearance rate and concentration of CA125 in the peritoneal effluent of APD patients treated with the neutral-pH, low-GDP solution balance versus a conventional PD solution.Entities:
Keywords: Biocompatibility; cancer antigen 125; pH neutral; peritoneal dialysis fluids; residual renal function; ultrafiltration
Mesh:
Substances:
Year: 2016 PMID: 27659931 PMCID: PMC5033636 DOI: 10.3747/pdi.2015.00010
Source DB: PubMed Journal: Perit Dial Int ISSN: 0896-8608 Impact factor: 1.756